Stocks · News reference
Stifel Initiates Coverage On Whitehawk Therapeutics with Buy Rating, Announces Price Target of $9
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Reported Sunday, Whitehawk's Real-World Data Show PTK7 Expression Remains Stable After Standard-Of-Care Therapies, Reinforcing Rationale For HWK-007 In EGFR Wild-Type NSCLC
PTK7 Expression Remained Stable Following Standard-of-Care Therapies, Supporting Its Relevance as a Target in Second- or Later-Line EGFR NSCLCFindings Reinforce the Scientific Rationale for HWK-007, Whitehawk's
8-K filing — Whitehawk Therapeutics, Inc. (WHWK)
Filed: 2026-09-10 AccNo: 0001193125-26-388010 Size: 168 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits